Most people think of
"viral therapy" as an obscure, experimental approach to the treatment
of disease. However, replicating viruses have been used as an effective
therapeutic modality for more than 200 years. One of the greatest clinical
advances in medical historythe eradication of smallpoxwas made with a
replicating virus. In 1796, Edward Jenner discovered that pus from the wounds of
infected patients contained live cowpox virus, which could be used as an
effective vaccine against smallpox. This discovery lead to the vaccination of
several million people and world clearance of the disease.
Interestingly, rare reports of complete remission induced in cancer patients
in association with smallpox vaccination were sporadically reported.
Observations of tumor regression in association with other viral infections have
also been described in cancer patients infected with herpes zoster,[4,5]
hepatitis virus,[6,7] influenza, varicella, measles,[10-12] and other
viruses.[13-15] The first published report of tumor destruction related to
replication competent viruses occurred in 1912 when a woman with cervical cancer
developed significant tumor necrosis following administration of an attenuated
rabies virus for prophylactic treatment after a dog bite.[16,17] Early in vitro
demonstration of viral oncolysis was first shown in 1922 with vaccinia virus,
which was shown to propagate in several malignant tumor lines.
Following these observations, extensive work was performed investigating the
potential use of viral therapy to treat cancer. In 1950, a strain of
encephalitis virus was shown to induce a dose-related oncolytic effect in vivo
with a mouse sarcoma tumor. Viral replication was shown to correlate with
tumor cell lysis; however, viral encephalitis developed in several mice. It was
later found that serial passaging of the encephalitis virus in vitro prior to
tumor injection in vivo would reduce the proliferative capacity in normal
tissues, thereby minimizing the occurrence of encephalitis and enhancing
oncolytic capacity. Clinical investigation was stimulated following additional
work with Newcastle disease virus (NDV), influenza virus, and other viruses in
animal models that showed cessation of ascites tumor (Ehrlich cells) growth and
eradication of the malignancy in some animals.[19-23]
Clinical trials were carried out in advanced cancer patients between 1950 and
the early 1970s, investigating administration of replication-proficient
viruses.[17,24-29] Transient responses were seen. Several mechanisms of action
were described, involving direct tumor lysis related to viral proliferation,
tumor antigen induced immune activation, modulation of cancer oncogene
expression (ie, c-fos, protein kinase C [PKC] modulation with measles
injection), apoptosis related to expression of unique viral proteins (ie,
E1A),[30,31] release of immunostimulatory cytokines,[32,33] and activation of
other antitumor immune responses (ie, natural killer [NK] cell activation).
Viruses with low pathogenicity for normal tissue and high oncolytic capacity
were investigated. Such viruses include NDV, mumps virus, herpes simplex virus (HSV),
Egypt 101 virus, influenza virus, adenovirus serotype 5, vaccinia, and ONYX-015.
Historical and current studies will be discussed.
Most oncolytic viruses require proliferation in the same species or cell
lineage and depend on host factors for successful evolution through life-cycle
stages (binding, entry, intracellular transport, genome replication, viral gene
expression, assembly and release of progeny). To initiate this process, the
virus requires a suitable receptor at the surface of the cell for uptake and
transcription factors to bind to the promoter/enhancer elements in the viral
genome, to induce expression of viral DNA.
Manipulations of the viral coat protein genes and tumor-specific viral
promoters have not adversely affected replication of oncolytic viruses in
malignant tissue, but have limited replication capacity in normal tissue.
Additional specificity to malignant tissue has been shown following modification
of the viral coat protein thereby enabling specific binding to tumor antigens
not expressed on normal cell surfaces, and engineering of tumor specific
promoter and enhancer regions with the viral genome to generate viruses with
selective malignant cell replication capacity.[37,38]
The release of oncolytic virus progeny (up to 104 viruses per cell) coincides
with the death of the host tumor cell. The first "burst" of
replicating viruses generally occurs less than 24 hours after treatment and
may continue as long as conditions are favorable for replication and immune
destruction of released virus is limited. Malignant cells are capable of evading
immune defenses, and this effect may facilitate local spread of released
Egypt 101 virus is a strain of the West Nile virus, which is an adenovirus
subtype. Preclinical testing of Egypt 101 virus in the early 1950s showed
oncolytic activity in a uterine/cervix cancer cell line (HeLa). Testing of
live virus administration via oral and intravenous routes in normal volunteers
revealed minimal toxicity (low-grade fever), thereby justifying clinical trials
in cancer patients,[42-44] although a small number of patients with hematologic
malignancies did develop transient encephalitis. Fever generally occurred
within 48 hours after inoculation and often coincided with the detection of live
virus in circulation or excretion.
In the first such trial, involving 34 cancer patients (27 evaluable for
response), tumor regression was observed in 4 patients, stabilization occurred
in 5, and 18 showed no response to a single injection of live virus. A
subsequent trial involving 30 patients with cervical carcinoma tested several
routes of inoculation (direct intratumoral injection, arterial infusion,
intravenous infusion).[43,45] Toxicity was limited to low-grade fever, and
regression or stabilization of disease was observed in the majority of patients.
Unfortunately, most responses were transient (< 3 months), and no patients
achieved a durable complete response.
Analysis of cervical tissue and vaginal smears revealed proliferating virus
in 77 samples from 20 patients studied. However, with analysis of 140 samples,
10 patients showed no evidence of viral presence. Response did not necessarily
correlate with recovery of virus, although patients achieving more extensive
necrosis generally harbored detectable virus. Studies to explore more intensive
dosing of the virus or combination with other anticancer agents were not
Mumps, a paramyxovirus, has a tight helical RNA inner core enclosed in an
outer lipid/protein shell. Oncolytic efficacy of mumps virus was initially
demonstrated in a rat sarcoma model.
The first clinical trial investigating mumps virus involved 90 patients with
advanced cancer and explored several routes of administration including oral,
rectal, intratumor, inhalation, and intravenous, depending on the location of
the tumor. Initial hematologic response to treatment included leukocytosis
followed by lymphopenia. Transient fever, which could be inhibited by
prophylactic treatment with low-dose prednisone, was also observed.
The authors noted that elevated antibodies at baseline were associated with a
lesser tumor response. However, three of the four patients achieving an
"optimal" response had elevated neutralizing antibodies to mumps virus
prior to treatment. Overall, 37 (41%) patients achieved a ³
50% reduction in tumor size, and 79 patients with stable disease or
better demonstrated clinical improvement (improved appetite, reduced pain,
increased body weight).
Of the 90 patients, 65 received a combination of local intratumoral injection
and/or intravenous infusion of the virus, and 24 (37%) of these 65 patients
showed a partial or complete response. Most partial or complete responses
occurred in patients with gastric carcinoma. However, the highest proportion of
complete or partial responses occurred in cutaneous carcinoma and uterine
carcinoma. Additionally, 9 of 10 patients with metastatic pulmonary carcinoma
achieved clinical improvement with regression in tumor bulk.
Patients receiving multiple intratumoral injections over a prolonged period
achieved a higher response rate and longer duration of response.[46,47] Fifteen
patients received intravenous mumps virus alone. Six of these patients received
fewer than nine intravenous treatments, and none had a positive response. In
contrast, of the nine patients receiving nine or more systemic treatments, six
achieved a response (P < .02). This was the first study to suggest that a
multitreatment administration schedule may have a clinical advantage.
Further exploration of a systemic route of administration was not performed.
A follow-up study involving 200 cancer patients administered mumps virus
intratumorally. Toxicity was minimal. Transient tumor regression was noted
in 26 patients. Responses were observed in patients with cancer of the breast,
rectum, colon, thyroid gland, uterus, and skin. Due to the transient nature of
the response and the difficulty in manufacturing a uniform product, further
clinical testing of the mumps virus was not pursued.
1. Niemialtowski MG, Toka FN, Malicka E, et al: Controlling orthopox virus
infections200 years after Jenner’s revolutionary immunization. Archivum
Immunologiae et Therapiae Experimentalis 44:373-378, 1996.
2. Ellner PD: Smallpox: Gone but not forgotten. Infection 26(5):263-269,
3. Hansen RM, Libnoch JA: Remission of chronic lymphocytic leukemia after
smallpox vaccination. Arch Intern Med 138:1137-1138, 1978.
4. Bousser J, Zittoun R: Remission spontanee prolongee D-une leucemie
lymphoide chromique. Nouv Rev Fr Hematol 5:498-501, 1965.
5. Vladimirskaia EB: A case of prolonged spontaneous remission in a patient
with chronic lymphocytic leukemia. Probl Gematol Pereliv Krovi 7:51-54, 1962.
6. Weintraub LR: Lymphosarcoma: Remission associated with viral hepatitis.
JAMA 24:1590-1591, 1969.
7. Sinkovics JG: Oncolytic viruses and viral oncolysates. Ann Immun
Hungaricae 26:271-290, 1986.
8. Dock G: Influence of complicating diseases upon leukaemia. Am J Med Sci
9. Bierman HR, Hammon WMcD, Eddie BU, et al: The effect of viruses and
bacterial infections on neoplastic diseases (abstract). Cancer Res 10:203-204,
10. Bluming AZ, Ziegler JL: Regression of Burkitt’s lymphoma in association
with measles infection. Lancet 2:105-106, 1971.
11. Taqi AM, Abdurraham MB, Yabubu AM, et al: Regression of Hodgkin’s
disease after measles. Lancet 1:1112, 1981.
12. Hernandez A: Observacion de un caso de enfermedad de Hodgkin, con
regresion de los sintomas e infartos ganglionares, post-sarampion. Rev Med
Cubana 60:120-125, 1949.
13. Bierman HR, Crile DM, Dod KS: Remissions in leukemia of childhood
following acute infectious disease; staphylococcus and streptococcus, varicella,
and feline panleukopenia. Cancer 6:591-605, 1953.
14. Pelner L, Fowler GA, Nauts HC: Effects of concurrent infections and their
toxins on the course of leukaemia. Acta Med Scand 338(suppl):1-47, 1958.
15. London RE: Multiple myeloma: report of a case showing unusual remission
lasting two years following severe hepatitis. Ann Intern Med 43:191-201, 1955.
16. De Pace NG: Sulla scomparsa di un enorme cancro vegetante del callo dell’utero
senza cura chirurgica. Ginecologia 9:82, 1912.
17. Pack GT: Note of the experimental use of rabies vaccine for melanomatosis.
Arch Dermatol Syphilol 62:694-695, 1950.
18. Moore AE: Inhibition of growth of five transplantable mouse tumors by the
virus of Russian far east encephalitis. Cancer 4:375-382, 1951.
19. Flanagan AD, Love R, Tesar W: Propagation of Newcastle disease virus in
Ehrlich ascites cells in vitro and in vivo. Proc Soc Biol Med 90:82-86, 1955.
20. Prince AM, Ginsberg HS: Immunohistochemical studies on the interaction
between Ehrlich ascites tumor cells and Newcastle disease virus. J Exp Med
21. Sinkovics J: Studies on the biological characteristics of the Newcastle
disease virus (NDV) adapted to the brain of newborn mice. Arch Ges Virusforsch
22. Ackermann W, Kurtz H: A new host-virus system. Proc Soc Exp Biol Med
23. Cassel WA: Multiplication of influenza virus in Ehrlich ascites
carcinoma. Cancer Res 17:618-622, 1957.
24. Southam CM: Present status of oncolytic virus studies. Trans NY Acad Sci
25. Asada T: Treatment of human cancer with mumps virus. Cancer
26. Moore AE: Carcinolytic viruses, in Harris RJC (ed): Biological Approaches
to Cancer Chemotherapy, pp 365-370. New York, Academic Press, 1961.
27. Sinkovics JG: in Die Grundlagen der Virusforschung, pp 98-103, 235-247.
Budapest, Ungarische Akademie der Wissenschaften, 1956.
28. Harris JE, Sinkovics JG (eds.): The Immunology of Malignant Disease, pp
180-182, 464-467, 475-478. St. Louis, Mosby, 1976.
29. Hoster HA, Zanes RP, von Haam E: Studies in Hodgkin’s syndrome. Cancer
Res 9:473-480, 1949.
30. Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced
by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7:535-545, 1993.
31. Yu D, Hamodo Y, Zhang H, et al: Mechanisms of c-erb B2/neu oncogene-induced
metastasis and repression of metastatic properties by adenovirus 5 E1A gene
products. Oncogene 7:2263-2270, 1992.
32. Lorence RM, Rood PA, Kelley KW: Newcastle disease virus as an
antineoplastic agent. Introduction of tumor necrosis factor-a and augmentation
of its cytotoxicity. J Natl Cancer Inst 80:1305-1312, 1988.
33. Sinkovics JG: Project M27/gm23: Production of human interferon. Research
Report, pp 332. Austin , Tex, M. D. Anderson Hospital University of Texas Press,
34. Sinkovics J, Horvath J: New development in the virus therapy of cancer: A
historical review. Intervirol 36:193-214, 1993.
35. Marsch M, Helenius A: Virus entry into animal cells. Adv Virus Res
36. Neda H, Wu CH, Wu GY: Chemical modification of an ecotropic murine
leukemia virus results in redirection of its target cell specification. J Biol
Chem 266:14143-14146, 1991.
37. Russell SJ, Brandenburger A, Fleming CL, et al: Transformation-dependent
expression of interleukin genes delivered by a recombinant parvovirus. J Virol
38. Friedman JM, Babiss LE, Clayton DF, et al: Cellular promoters
incorporated into the adenovirus genome: cell specificity of albumin and
immunoglobulin expression. Mol Cell Biol 6:3791-3797, 1986.
39. Peplinski GR, Tsung K, Norton JA: Vaccinia virus for human gene therapy.
Cancer Gene Ther 7(3):575-588, 1998.
40. North RJ: Down regulation of the anti-tumor immune response. Adv Cancer
Res 45:1-37, 1985.
41. Scherer WF, Syverton JT, Gey GO: Studies on the propagation in vitro of
poliomyelitis viruses. IV. Viral multiplication in a stable strain of human
malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of
the cervix. J Exper Med 97:695-709, 1953.
42. Southam CM, Moore AE: Clinical studies of viruses as antineoplastic
agents with particular reference to Egypt 101 virus. Cancer 5:1025-1034, 1952.
43. Smith RR, Huebner JR, Rowe WP, et al: Studies on the use of viruses in
the treatment of carcinoma of the cervix. Cancer 9:1211-1218, 1956.
44. Sinkovics JG: Oncogenes-antioncogenes and virus therapy of cancer.
Anticancer Res 9:1281-1290, 1989.
45. Russell SJ: Replication vectors for gene therapy of cancer: Risks,
limitations and prospects. Eur J Cancer 30A(8):1165-1171, 1994.
46. Csatary LK, Eckhardt S, Bukosza I, et al: Attenuated veterinary virus
vaccine for the treatment of cancer. Cancer Detect Prev 17(6):619-627, 1993.
47. Csatary LK, Gergely P: Virus vaccines for the treatment of cancer. Orv
Hetil 131:2585-2588, 1990.
48. Shimizu Y, Hasumi K, Okudaira Y: Immunotherapy of advanced gynecologic
cancer patients utilizing mumps virus. Cancer Detect Prev 12:487-495, 1988.
49. Okuno Y, Asada T, Yamanishi K: Studies on the use of mumps virus for
treatment of human cancer. Biken J 21:37-49, 1978.
50. Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic
agent. Cancer 18(7):863-868, 1965.
51. Reichard KW, Lorence RM, Cascino CJ: N-myc oncogene enhances the
sensitivity of neuroblastoma to killing by Newcastle disease virus. Surg Forum
52. Heicappell R, Schirmacher V, Von Hoegen P: Prevention of metastatic
spread by postoperative immunotherapy with virally modified autologous tumor
cells. I. Parameters for optional therapeutic effects. Int J Cancer 37:569-577,
53. Von Hoegen P, Weber E, Schirrmacher V: Modification of tumor cells by a
low dose of Newcastle disease virus. Augmentation of the tumor-specific T-cell
response in the absence of anti-viral response. Eur J Immunol 18:1159-1166,
54. Schirmacher V, Ahlert T, Heicappell R: Successful application of non-oncogenic
virus for antimetastatic cancer immunotherapy. Cancer Rev 5:19-32, 1986.
55. Bar-Eli N, Giloh H, Schlesinger M, et al: Preferential cytotoxic effect
of Newcastle disease virus on lymphoma cells. Cancer Res Clin Oncol 122:409-415,
56. Tzadok-David Y, Metzkin-Eizenberg M, Zakay-Rones Z: The effect of a
mesogenic and a lentogenic Newcastle disease virus strain of Burkitt lymphoma
Daudi cells. Cancer Res Clin Oncol 121:169-174, 1995.
57. Reichard KW, Lorence RM, Cascino CJ, et al: Newcastle disease virus
selectively kills human tumor cells. J Surg Res 52:448-453, 1992.
58. Sinkovics J, Howe CD: Super-infection of tumors with viruses. Experientia
59. Cassel WA, Murray DR, Phillips HS: A phase II study on the post-surgical
management of stage II malignant melanoma with a Newcastle disease virus
oncolysate. Cancer 52(5):856-860, 1983.
60. Cassel WA, Murray DR: A ten-year follow-up on stage II malignant melanoma
patients treated post-surgically with Newcastle disease virus oncolysate. Med
Oncol Tumor Pharmacother 9:169-171, 1992.
61. Cassell WA, Murray DR: Letter to the editor. Nat Immun Cell Growth Regul
62. Schlag P, Manasterski M, Gerneth T, et al: Active specific immunotherapy
with Newcastle disease virus modified autologous tumor cells following resection
of liver metastases in colorectal cancer. First evaluation of clinical response
of a phase II trial. Cancer Immunol Immunother 35:325-330, 1992.
63. Kirschner HH, Anton P, Atzpodien J: Adjuvant treatment of locally
advanced renal cancer with autologous virus-modified tumor vaccines. World J
Urol 13:171-173, 1995.
64. Haas C, Straus G, Moldenhauer G, et al: Biospecific antibodies increase
T-cell stimulatory capacity in vitro of human autologous virus-modified tumor
vaccine. Clin Cancer Res 4:721-730, 1998.
65. Haas C, Schirrmacher V: Immunogenicity increase of autologous tumor cell
vaccines by virus infection and attachment of bispecific antibodies. Cancer
Immunol Immunother 43:190-194, 1996.
66. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting
the immunopotentiating effects of cyclophosphamide. Cancer Inv 6:337-349, 1988.
67. Hoover SK, Barrett SK, Turk TMT, et al: Cyclophsphamide and abrogation of
tumor-induced suppressor T-cell activity. Cancer Immunol Immunother 31:121-127,
68. Freedman RS, Edwards CL, Bowen JM, et al: Viral oncolysates in patients
with advanced ovarian cancer. Gynecol Oncol 29:337-347, 1988.
69. Cassel WA, Garrett RE: Relationship between viral neurotropism and
oncolysis. II. Study of Influenza virus. Cancer 20(3):440-444, 1967.
70. Boone CW: Augmented immunogenicity of tumor cell homogenates infected
with influenza virus. Recent Results Cancer Res 47:394-400, 1974.
71. Ioannides CG, Platsoucas CD, Patenia R, et al: T-cell functions in
ovarian cancer patients treated with viral oncolysates: I. Increased helper
activity to immunoglobulins production. Anticancer Res 10:645-654, 1990.
72. Goebel SJ, Johnson GP, Perkus ME: The complete DNA sequence of vaccinia
virus. Virol 179:247-266, 1990.
73. Wallack MK, Steplewski Z, Koprowski H, et al: A new approach in specific,
active immunotherapy. Cancer 39:560-564, 1977.
74. Wallack MK, Sivanandham M, Balch CM, et al: Surgical adjuvant active
specific immunotherapy for patients with stage III melanoma: The final analysis
of data from a phase III randomized double-blind, multicenter vaccinia melanoma
oncolysate trial. Am J Coll Surg 187(1):69-79, 1998.
75. Cassel WA, Garrett RE: Relationship between viral neurotropism and
oncolysis. I. Study of vaccinia virus. Cancer 20(3):433-439, 1967.
76. Cassell WA, Murray DR, Torbin AH, et al: Viral oncolysate in the
management of malignant melanoma. I. Preparation of the oncolysate and
measurement of immunologic responses. Cancer 40(2):672-679, 1977.
77. Barnavon Y, Iwaki H, Bash JA, et al: Treatment of murine hepatic
metastases with vaccinia colon oncolysate and IL-2. J Surg Res 45:523, 1988.
78. Barnavon Y, Iwaki H, Bash JA, et al: Vaccinia colon oncolysate
immunotherapy for murine hepatic metastases can be modulated with low-dose
interleukin-2. Am Surg 54:696, 1988.
79. Wu KS, Ueda S, Skaue Y: Prevention of syngeneic tumor growth in vaccinia
virus-modulated tumor cells. Biken J 24:153-158, 1981.
80. Shimizu Y, Fujiwara H, Ueda S: The augmentation of tumor-specific
immunity by virus help. II. Enhanced induction of cytotoxic T-lymphocyte and
antibody to tumor antigens by vaccinia virus-reactive helper T-cells. Eur J
Immunol 14:839-843, 1984.
81. Wallack MK, Bash JA, Leftheriotis E, et al: Positive relationship of
clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg
82. Wallack MK, Michaelides MC: Serologic responses to human melanoma line
from patients with melanoma undergoing treatment with vaccinia melanoma
oncolysates. Surg 96:791-799, 1984.
83. Wallack MK, Meyer M, Burgoin A: A preliminary trial of vaccinia
oncolysates in the treatment of recurrent melanoma with serologic responses to
the treatment. J Biol Response Mod 2:586-596, 1983.
84. Wallack MK, McNally KR, Leftheriotis E: A Southeastern Cancer Study Group
phase I/II trial with vaccinia melanoma oncolysates. Cancer 57:649-655, 1986.
85. Wallack MK, Scoggin SD, Sivanandham M: Active specific immunotherapy with
vaccinia melanoma oncolysate. Mount Sinai J Med 59(3):227-233, 1992.
86. Scoggin SD, Sivanandham M, Sperry RG, et al: Active specific adjuvant
immunotherapy with vaccinia melanoma oncolysate. Ann Plast Surg 28:108-109,
87. Mastrangelo MJ, Maguire HC, Mccue P, et al: Intratumoral (IT) recombinant
GM-CSF encoding vaccinia virus as gene therapy in patients (pts) with melanoma
(abstract 1660). Proc Am Soc Clin Oncol 18:431, 1999.
88. Palella TD, Silverman L, Schroll CT, et al: Herpes simplex virus-mediated
human hypoxanthine-guanine phosphoribosyltransferase gene transfer into neuronal
cells. Mol Cell Biol 8(1):457-460, 1988.
89. Geller AI, Breakefield WX: A defective HSV-1 vector expresses Escherichia
coli beta-galactosidase in cultured peripheral neurons. Science 241:1667-1669,
90. Coen DM, Kosz-Vnenchak M, Jacobson JG, et al: Thymidine kinase-negative
herpes simplex virus mutants establish latency in mouse trigeminal ganglia but
do not reactivate. Proc Natl Acad Sci USA 86:4736-4740, 1989.
91. Martuza RL, Malick A, Markert JM, et al: Experimental therapy of human
glioma by means of a genetically engineered virus mutant. Science 252:854-856,
92. Jamieson AT, Gentry GA, Subak-Sharpe JH: Biochemical studies on the
herpes simplex virus-specified deoxypyrimidine kinase activity. J Gen Virol
93. Field HJ, Wildy P: The pathogenicity of thymidine kinase-deficient
mutants of herpes simplex virus in mice. J Hyg (London) 81(2):267-277, 1978.
94. Jia WAG, McDermott M, Goldie J, et al: Selective destruction of gliomas
in immunocompetent rats by thymidine kinase-defective herpes simplex virus type
1. J Natl Cancer Inst 86(16):1209-1215, 1994.
95. Mineta T, Rabkin SD, Yazaki T, et al: Attenuated multimutated herpes
simplex virus-1 for the treatment of malignant gliomas. Nature Med 1(9):938-943,
96. Toda M, Rabkin SD, Martuza RL: Treatment of human breast cancer in a
brain metastatic model by G207, a replication-competent multimutated herpes
simplex virus 1. Hum Gene Ther 9:2177-2185, 1998.
97. Randazzo B, Kesari Sa, Gesser RM, et al: Treatment of experimental
intracranial murine melanoma with a neuroattenuated herpes simplex virus 1
mutant. Virol 211:94-101, 1995.
98. Yazaki T, Manz HJ, Radbin SD, et al: Treatment of human malignant
meningiomas by G207, a replication-competent multimutated herpes simplex virus
1. Cancer Res 55:4752-4756, 1995.
99. Coukos G, Makrigiannakis A, Kang E, et al: Producer cells enhance the
oncolytic effect of a replication-competent ICP34.5-null herpes simplex vurus-1
(HSV-1) strain in epithelial ovarian cancer (abstract O-21). Cancer Gene Ther
100. Toyoizumi T, Abbas AE, Caparrelli DJ, et al: Combination therapy with
herpes simples virus type 1 ICP34.5 mutant (HSV-1716) and common
chemotherapeutic agents for human non-small cell lung cancer (NSCLC) (abstract
O-22). Cancer Gene Ther 5(6):S7, 1998.
101. Fang X, Alemany R, Lai S, et al: Development of novel oncolytic
dual-adenovirus vector for gene therapy of cancer (abstract O-23). Cancer Gene
Ther 5(6):S8, 1998.
102. Toda M, Martuza RL, Kojima H, et al: In situ cancer vaccination: An
IL-12 defective vector/replication-competent herpes simplex virus combination
induces local and systemic antitumor activity. J Immunol 160:4457-4464, 1998.
103. Ichikawa T, Ikeda K, Chung RY, et al: Comparing gene transduction and
viral replication within large subcutaneous human glioma inoculated with a
replication-defective versus a replication-conditional herpes simplex virus type
1 vector (abstract PD-33). Cancer Gene Ther 5(6):S11, 1998.
104. Ikeda K, Silver J, Ichikawa T, et al: Intravascular delivery of
oncolytic viral vectors for selective and efficient transduction of human and
rodent brain tumors (abstract PD-34). Cancer Gene Ther 5(6):S11, 1998.
105. Brandt CD, Kim HW, Vargosko AJ, et al: Infections in 18,000 infants and
children in controlled study of respiration tract disease. Adenovirus
pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol
106. Hierholzer JC: Adenoviruses in the immunocompromised host. Clin
Microbiol Rev 5:262-274, 1992.
107. Takafuji ET: Simultaneous administration of live, enteric-coated
adenovirus types 4, 7, and 21 vaccines: Safety and immunogenicity. J Infect Dis
108. Green M, Wold WS, Mackey JK, et al: Analysis of human tonsil and cancer
DNAs and RNAs for DNA sequences in group C (serotypes 1, 2, 5 and 6) human
adenoviruses. Proc Natl Acad Sci USA 76(12):6606-6610, 1979.
109. Lesoon-Wood LA, Kim WH, Kleinman HK: Systemic gene therapy with p53
reduces growth and metastases of a malignant human breast cancer in nude mice.
Hum Gene Ther 6:395-405, 1995.
110. Zhang W, Alemany R, Wang J: Safety evaluation of AdCMV-p53 in vitro and
in vivo. Hum Gene Ther 6:155-164, 1995.
111. Nielsen LL, Dell J, Maxwell E: Efficacy of p53 adenovirus-mediated gene
therapy against human breast cancer xenografts. Cancer Gene Ther 4(2):129-138,
112. Simon RH, Engelhardt JF, Yang Y: Adenovirus-mediated transfer of the
CFRT gene to lung of non-human primates: Toxicity study. Hum Gene Ther
113. Xu M, Kumar D, Srinivas S: Parenteral gene therapy with p53 inhibits
human breast tumor in vivo through a bystander mechanism without evidence of
toxicity. Hum Gene Ther 8:177-185, 1998.
114. Gomez-Foix AM, Coats WS, Baque S: Adenovirus-mediated transfer of the
muscle glycogen phosphorylate gene into hepatocytes confers altered regulation
of glycogen. J Biol Chem 267:25129-25134, 1992.
115. Le Gal La Salle G, Robert JJ, Bernard S: An adenovirus vector for gene
transfer into neurons and glia in the brain. Science 259:988-990, 1993.
116. Tursz T, Le Cesne A, Baldeyrou P: Phase I study of a recombinant
adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst
117. Harvey BG, Worgall S, Ramirez M: Host responses to intradermal
administration of a first generation replication deficient adenovirus vector to
normal individuals (abstract). Am Soc Gene Ther 167:43a, 1998.
118. Nemunaitis J, Swisher SG, Timmons T, et al Adenovirus-mediated p53 gene
transfer in sequence with cisplatin to tumors of patients with non-small-cell
lung cancer. J Clin Oncol 18(3):609-622, 2000.
119. Swisher SG, Roth JA, Nemunaitis J, et al Adenoviral-mediated p53 gene
transfer in non-small cell lung cancer. J Natl Cancer Inst 91(9):763-771, 1999.
120. Lechner MS, Mack DH, Finicle AB, et al: Human papilloma virus E6
proteins bind p53 in vivo and abrogate p53-mediated repression of transcription.
EMBO J 11:3045-3052, 1992.
121. Gannon JV, Lane DP: p53 and DNA polymerase alpha compete for binding to
SV40 T antigen. Nature 329:456-458, 1987.
122. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are
required for transformation of rodent cells by viral infection and DNA
transfection. Virology 156:107-121, 1987.
123. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that
replicates selectively in p53-deficient human tumor cells. Science 274:373-376,
124. Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, an E1B
gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral
efficacy that can be augmented by standard chemotherapeutic agents. Nat Med
125. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of
chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated
transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994.
126. You L, Yang C-T, Jablons DM: ONYX-015 works synergistically with
chemotherapy in lung cancer cell lines and primary cultures freshly made from
lung cancer patients. Cancer Res 60:1009-1013, 2000.
127. Heise CC, Williams AM, Xue S, et al Intravenous administration of
ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.
Cancer Res 59:2623-2628, 1999.
128. Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, and E1B gene
attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy
that can be augmented by standard chemotherapeutic agents. Nat Med 3(6):639-645,
129. Goodrum FD, Ornelles DA: The early region 1B 55-kilodalton oncoprotein
of adenovirus relieved growth restrictions imposed on viral replication on viral
replication by the cell cycle. J Virol 71:548-561, 1997.
130. Hall AR, Dix BR, O’Carroll SJ, et al: P53 dependent cell
death/apoptosis is required for a productive adenovirus infection. Nat Med
131. Turnell AS, Grand RJ, Gallimore PH: The replicative capacities of large
E1B-null group A and group C adenoviruses are independent of host cell p53
status. J Virol 73:2074-2083, 1999.
132. Leach FS, Tokino T, Meltzer P, et al: P53 mutation and MDM2
amplification in human soft tissue sarcomas. Cancer Res 53(10):2231-2234, 1993.
133. Koch WM, Boyle JO, Mao L, et al: P53 gene mutations as markers of tumor
spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg
134. Brennan JA, Boyle JO, Koch WM, et al: Association between cigarette
smoking and mutation of the p53 gene in squamous cell carcinoma of the head and
neck. N Engl J Med 332(11):712-717, 1995.
135. Vonlanthen S, Heighway J, Tschan MP, et al: Expression of the
p161INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell
lung cancer and correlates with p53 overexpression. Oncogene 17(21):2779-2785,
136. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degreadation and
stabilized p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor
suppresion pathways. Cell 92:725-734, 1998.
137. Harada J, Berk AJ: P35-independent and -dependent requirements for
E1B-55kD in adenovirus type 5 replication. J Virol 73:5333-5344, 1999.
138. Kirn D, Hermiston T, McCormick F: ONYX-015: Clinical data are
encouraging. Nat Med 4:1341-1342, 1998.
139. Nemunaitis J, Ganly I, Khuri F, et al: Selective replication and
oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted
adenovirus, in patients with advanced head and neck cancer: A phase II trial.
Cancer Res 60(22):6359-6366, 2000.
140. Ganly I, Kirn D, Echhardt G, et al: A phase I study of ONYX-015, an E1B
attenuated adenovirus, administered intratumorally to patients with recurrent
head and neck cancer. Clin Cancer Res 6:798-806, 2000.
141. Nemunaitis J, Khuri F, Ganly I, et al: A phase II trial of intratumoral
injection of ONYX-015 in patients with refractory head and neck cancer. J Clin
Oncol 19(2):289-298, 2001.
142. Khuri F, Nemunaitis J, Ganly I, et al: A controlled trial of
intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with
cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat Med
143. Nemunaitis J, Cunningham C, Buchanan A, et al: Intravenous infusion of a
replication-selective adenovirus (ONYX-015) in cancer patients: Safety,
feasibility, and biological activity. Gene Ther 8:746-759, 2001.